Guadeloupe vs Tajikistan: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Guadeloupe
0.2%
in 2024
Tajikistan
0.2%
in 2024
Guadeloupe rank
99th
Tajikistan rank
99th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Guadeloupe
- Tajikistan
How they compare
Guadeloupe currently reports 0.2% against 0.2% in Tajikistan, a difference of 0.0%.
Across all 10 years both countries report, Tajikistan has been ahead every year.
Guadeloupe ranks 99th and Tajikistan ranks 99th of 247 countries.
Tajikistan has averaged higher in every one of the 2 decades both report.
Head to head by decade
| Decade | Guadeloupe | Tajikistan | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | Tajikistan |
| 2020s | 0.2% | 0.2% | 0.0% | — |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Guadeloupe or Tajikistan?
- Guadeloupe, at 0.2% against 0.2% in Tajikistan as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Guadeloupe and Tajikistan?
- 0.0%, with Guadeloupe ahead.
- How many years of comparable data are there for Guadeloupe and Tajikistan?
- 10 years are reported by both, from 2015 to 2024.
- How do Guadeloupe and Tajikistan rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Guadeloupe ranks 99th and Tajikistan ranks 99th of 247 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.